También podría leer
Artículos Relacionados
Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.
Ordenar por
Same author
Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patients.
Journal of cancer policy·2025
Same author
REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma.
ESMO open·2024
Same author
Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients.
ESMO open·2023
Same author
Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients.
ESMO open·2023
Same author
Metronomic Temozolomide in Heavily Pretreated Patients With Recurrent Isocitrate Dehydrogenase Wild-type Glioblastoma: A Large Real-Life Mono-Institutional Study.
Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author
Position paper of the Italian Association of Medical Oncology on the impact of COVID-19 on Italian oncology and the path forward: the 2021 Matera statement.
ESMO open·2022
Same journal
Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.
Lancet (London, England)·2026
Same journal
[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.
Lancet (London, England)·2026
Same journal
Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.
Lancet (London, England)·2026
Same journal
Dual mobility total hip replacement in fractures: stability promotes patient confidence.
Lancet (London, England)·2026


